RESUMO
AIMS: Transthyretin cardiac amyloidosis (ATTR-CA) is a rare and progressive cardiomyopathy caused by amyloid fibril deposition in myocardial tissue. Diagnostic challenges have historically hampered timely detection. Recent advances in noninvasive diagnostic techniques have facilitated ATTR-CA diagnosis. We aimed to examine the development of a regional network for the diagnosis and management of ATTR-CA and describe a cohort of patients with ATTR-CA, investigate diagnostic pathways and assess clinical outcomes according to diagnosis periods. METHODS: We performed a survey study analyzing answers from 11 cardiology centers and we conducted a retrospective study including patients with ATTR-CA attending a referral center between 1 January 2012 and 31 December 2022, and categorized by the period of diagnosis (2012-2016 and 2017-2022). RESULTS: Over the years, a growing number of patients reached a diagnosis and were treated in the surveyed nonreferral centers of the region. The retrospective study showed a more significant diagnostic delay in the earlier period rather than the later one [13.4 (5-30.2) vs. 10.6 (5.0-17.9) months, P = 0.04]. Patients diagnosed after 2017 showed a greater survival rate than those diagnosed earlier ( P = 0.02). In the multivariate analysis, the year of diagnosis from 2017 remained independently associated with mortality [hazard ratio (HR) 0.46, 95% confidence interval (CI) 0.28-0.79; P = 0.005]. CONCLUSION: This study emphasized the shift toward noninvasive diagnostic criteria. It revealed a positive impact on patient survival and disease management with the use of disease-modifying therapies and diagnostic developments in more recent years. The findings underscore the importance of disease awareness and networking to reduce diagnostic delays and enhance patient journeys for ATTR-CA.
Assuntos
Neuropatias Amiloides Familiares , Cardiomiopatias , Diagnóstico Tardio , Encaminhamento e Consulta , Humanos , Estudos Retrospectivos , Neuropatias Amiloides Familiares/diagnóstico , Neuropatias Amiloides Familiares/terapia , Neuropatias Amiloides Familiares/mortalidade , Masculino , Cardiomiopatias/diagnóstico , Cardiomiopatias/terapia , Feminino , Idoso , Encaminhamento e Consulta/estatística & dados numéricos , Fatores de Tempo , Itália , Pessoa de Meia-Idade , Idoso de 80 Anos ou mais , Pesquisas sobre Atenção à Saúde , Tempo para o Tratamento , Valor Preditivo dos Testes , Procedimentos ClínicosRESUMO
The study was performed to evaluate the impact of cardiological disorders on the outcome of myasthenic crisis (MC) requiring ventilation. The study includes 90 cases admitted to the Neurology Unit of Modena, Italy (January 2000 - September 2020). All patients were eligible for a non-invasive ventilation (NIV) trial. We analyzed the effect of cardiac comorbidities on the outcomes, which were the need of invasive ventilation, the risk tracheostomy for weaning failure and the duration of intensive care unit (ICU) stay Females were 58.9% and males 41.1%. Median age at diagnosis was 59 and at MC was 65. Patients were classified as early (EOMG) or late (LOMG), 34.4 and 65.6% respectively, according to age above or below 50; 85% of patients were anti- AChR antibody positive. Hypertension and cardiac diseases occurred at the diagnosis in 61 and 44.4%, respectively. Invasive mechanical ventilation (MV) was needed in 34% of cases. Nine subjects (10%) underwent tracheostomy because of weaning failure. Independent predictors of NIV failure were atrial fibrillation (AF), either parossistic or persistent (OR 3.05, p < 0.01), hypertensive cardiopathy (HHD) (OR 2.52, p < 0.01) and ischaemic heart disease (IHD) (OR 3.08, p < 0.01). Hypertension (HT) had no statistical effect on the outcomes. HHD was a predictor of weaning failure (OR 4.01, p = 0.017). Our study shows that HHD, AF and IHD increase the risk of NIV failure in MC receiving ventilation.
Assuntos
Fibrilação Atrial , Hipertensão , Miastenia Gravis , Ventilação não Invasiva , Feminino , Humanos , Hipertensão/epidemiologia , Hipertensão/terapia , Masculino , Miastenia Gravis/complicações , Miastenia Gravis/terapia , Respiração Artificial , Estudos RetrospectivosRESUMO
BACKGROUND: The Oxford-AstraZeneca vaccine ChAdOx1 (AZD1222, Vaxzevria) is playing a crucial role in counteracting the coronavirus disease-2019 (COVID-19) pandemic [1]. Since March 2021, reports of unexpected thrombotic events associated with thrombocytopenia and vaccination have been published [2]. To the best of our knowledge there is only one report about vaccination-associated myasthenia gravis (MG) occurring after a second dose of BNT162b2 (Pfizer-BioNTech).
Assuntos
COVID-19 , ChAdOx1 nCoV-19 , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/diagnóstico , Miastenia Gravis , Brometo de Piridostigmina/administração & dosagem , Idoso , COVID-19/epidemiologia , COVID-19/prevenção & controle , Vacinas contra COVID-19/administração & dosagem , Vacinas contra COVID-19/efeitos adversos , Vacinas contra COVID-19/imunologia , ChAdOx1 nCoV-19/administração & dosagem , ChAdOx1 nCoV-19/efeitos adversos , ChAdOx1 nCoV-19/imunologia , Inibidores da Colinesterase/administração & dosagem , Diagnóstico Diferencial , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/etiologia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/imunologia , Febre/etiologia , Febre/terapia , Humanos , Masculino , Mialgia/etiologia , Mialgia/terapia , Miastenia Gravis/diagnóstico , Miastenia Gravis/tratamento farmacológico , Miastenia Gravis/imunologia , Miastenia Gravis/fisiopatologia , SARS-CoV-2 , Resultado do TratamentoRESUMO
About 20% of patients with myasthenia gravis (MG) may develop myasthenic crisis (MC) requiring ventilation, either invasive (MV) or non-invasive (NIV) and intensive unit care (ICU). NIV failure in patients with MC can occur up to 60% of cases admitted to ICU. Moreover it is not known the outcome of MC receiving NIV. Purpose of this study was to identify predictors of outcome in MC who underwent non-invasive ventilator support outside ICU setting. We enrolled 90 patients, 53 females and 37 males admitted to University Hospital of Modena (Italy) between January 2000 and September 2020. Median age at MC was 65 years. Thirty-four patients (37.8%) required MV. Thymectomy was performed in 45 cases, associated with thymoma in 55%, with hyperplastic thymus in 33%. First-line treatment was plasmaexchange (38.8%) or intravenous immunoglobulins (45.6%). Males exhibited higher risk of MV than females .Patients in MV were treated with plasmaexchange as first-line therapy . Our in-hospital mortality rate was low. Nine patients underwent tracheostomy which was significantly related to male gender. Comorbidities had significant effect on length of ICU .Our study confirms as predictors of prognosis in our patients male gender, older age at onset, infections as trigger, pneumonia.
Assuntos
Miastenia Gravis/diagnóstico , Miastenia Gravis/terapia , Ventilação não Invasiva , Avaliação de Resultados em Cuidados de Saúde , Idoso , Feminino , Humanos , Itália/epidemiologia , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Miastenia Gravis/epidemiologia , Ventilação não Invasiva/estatística & dados numéricos , Prognóstico , Estudos RetrospectivosAssuntos
Linfoma Difuso de Grandes Células B/complicações , Degeneração Paraneoplásica Cerebelar/etiologia , Atrofia/diagnóstico por imagem , Cerebelo/patologia , Feminino , Humanos , Espectroscopia de Ressonância Magnética , Pessoa de Meia-Idade , Degeneração Paraneoplásica Cerebelar/diagnóstico por imagemRESUMO
An unsolved issue remains whether there are clinical and immunological features to predict in a single patient the risk of conversion from ocular Myasthenia Gravis (OMG) to generalized disease (GMG) as 50-60% of patients may progress within 1-2 years since onset. Anti-acetylcholine receptor antibodies (AChR Abs) are found in up to 50% of OMG patients; muscle-specific tyrosine kinase antibodies (MuSK-Abs) are present in about 70% of the whole seronegative (SN), who usually develop a severe disease with bulbar involvement. We surveyed a cohort of 175 OMG patients with purely ocular symptoms and we compare the outcome of patients with antibodies to AChR or to MuSK with those seronegative for both Abs (DSN). All patients had purely ocular signs for at least 24 months. Gender, age at onset, time to generalization or to worsening in quantitative ocular QMG scores, electrophysiological results were analyzed. Males were 58.9%, females 41.1%. Patients with late onset of symptoms after 50 years (LOMG) were 78.3%. We assayed anti-MuSK-Abs in 4.7%, anti-AChR Abs in 38.5%; 57.3% were defined DSN. Thirty-seven patients (21.1%) progressed to GMG during the observational time: 23 were females, 62% of the whole group of the generalized subjects, 75% of MuSK-positive OMG converted to GMG versus the 26.2% of AChR positive and 13.7% of DSN. Statistical analysis showed that gender and presence of antibodies either to AChR or to MuSK were independent predictors of worse outcome; the DSN subjects had lower risk of conversion to GMG.
Assuntos
Autoanticorpos/metabolismo , Miastenia Gravis/diagnóstico , Valor Preditivo dos Testes , Receptores Proteína Tirosina Quinases/metabolismo , Receptores Colinérgicos/metabolismo , Adulto , Idoso , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Risco , Adulto JovemRESUMO
AIM OF THE STUDY: 50%-60% of patients with ocular myasthenia gravis (OMG) progress to generalized myasthenia gravis (GMG) within two years. The aim of our study was to explore factors affecting prognosis of OMG and to test the predictive role of several independent clinical variables. MATERIALS AND METHODS: We reviewed a cohort of 168 Caucasian patients followed from September 2000 to January 2016. Several independent variables were considered as prognostic factors: gender, age of onset, results on electrophysiological tests, presence and level of antibodies against acetylcholine receptors (AChR Abs), treatments, thymic abnormalities. The primary outcome was the progression to GMG and/or the presence of bulbar symptoms. Secondary outcomes were either achievement of sustained minimal manifestation status or worsening in ocular quantitative MG subscore (O-QMGS) or worsening in total QMG score (T-QMGS), assessed by Myasthenia Gravis Foundation of America (MGFA) quantitative scores. Changes in mental and physical subscores of health-related quality of life (HRQoL) were assessed with SF-36 questionnaire. Variance analysis was used to interpret the differences between AChR Ab titers at different times of follow up among the generalized and non-generalized patients. RESULTS: Conversion to GMG occurred in 18.4% of patients; it was significantly associated with sex, later onset of disease and anti-AChR Ab positivity. Antibody titer above the mean value of 25.8 pmol/mL showed no significant effect on generalization. Sex and late onset of disease significantly affected T-QMGS worsening. None of the other independent variables significantly affected O-QMGS and HRQoL. CONCLUSIONS: Sex, later onset and anti-AChR Ab positivity were significantly associated with clinical worsening.
Assuntos
Autoanticorpos/sangue , Progressão da Doença , Glucocorticoides/uso terapêutico , Imunossupressores/uso terapêutico , Miastenia Gravis , Avaliação de Resultados em Cuidados de Saúde , Receptores Colinérgicos/imunologia , Índice de Gravidade de Doença , Adolescente , Adulto , Idade de Início , Idoso , Idoso de 80 Anos ou mais , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Miastenia Gravis/sangue , Miastenia Gravis/tratamento farmacológico , Miastenia Gravis/patologia , Miastenia Gravis/fisiopatologia , Estudos Retrospectivos , Fatores Sexuais , Adulto JovemRESUMO
AIM OF THE STUDY: Neuropathy associated with IgM monoclonal gammopathy (MGUS) represents distinctive clinical syndrome, characterized by male predominance, late age of onset, slow progression, predominantly sensory symptoms, deep sensory loss, ataxia, minor motor impairment. More than 50% of patients with neuropathy-associated MGUS possess antibodies against myelin-associated glycoprotein (MAG). Purpose of our study was to assess effects on disease progression of demographic, clinical and neurophysiological variables in our large cohort of patients. MATERIALS AND METHODS: Forty-three Caucasians patients were followed every eight months for median duration time of 93 months. Extremity strength was assessed with Medical Research Council (MRC) Scale, disability with overall disability status scale (ODSS), modified Rankin Scale and sensory function with Inflammatory Neuropathy Cause and Treatment (INCAT) sensory scale (ISS). Statistical analyses were conducted with parametric or non-parametric measures as appropriate. Survival analysis was used to test predictive value of clinical, demographical and neurophysiological variables. Variance analysis was conducted to explain difference on MRC between patients and groups at different time from onset. RESULTS: Results showed that demyelinating pattern, older age and absence of treatment were significant risk factors for disability worsening. No other factors emerged as predictors including gender, ataxia and tremor at baseline, level of anti-MAG and IgM protein concentration in serum. Despite worsening of all outcome measures between first and last visit, quality of life (HRQol) judged by patients did not vary significantly. CONCLUSIONS: Our study provides evidence that electrophysiologic pattern, age of onset and absence of treatment are strong predictor of prognosis in anti-MAG polyneuropathy.
Assuntos
Anticorpos/sangue , Pessoas com Deficiência , Glicoproteína Associada a Mielina/imunologia , Polineuropatias/sangue , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Avaliação da Deficiência , Feminino , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Polineuropatias/complicações , Polineuropatias/diagnóstico , Análise de Regressão , Índice de Gravidade de DoençaAssuntos
Neoplasias da Mama/imunologia , Carcinoma Ductal de Mama/imunologia , Mielite Transversa/imunologia , Proteínas do Tecido Nervoso/imunologia , Síndromes Paraneoplásicas/imunologia , Adulto , Autoanticorpos/imunologia , Autoantígenos , Doenças Autoimunes/imunologia , Autoimunidade/imunologia , Western Blotting , Neoplasias da Mama/complicações , Carcinoma Ductal de Mama/complicações , Feminino , Humanos , Imuno-Histoquímica , Imageamento por Ressonância MagnéticaRESUMO
We evaluate the factors predictive of prognosis in 91 Caucasian patients affected by ocular myasthenia gravis (OMG), followed at our Institution during an observational time, ranging from 12 to 240 months. The Myasthenia Gravis Foundation of America (MGFA) clinical classification was used to grade the disease severity. We considered as outcome measures the variation in two subscores, ocular (O-QMG) and nonocular (NO-QMG); the last one reflected bulbar, neck, extremity functions. None of the independent variables evaluated for association with the outcome, as age of onset, type of therapy, length of interval between first and last examinations, and presence of antibodies to acetylcholine receptors (AChR-Abs) significantly affected the evolution of O-QMG and of NO-QMG. Health-related quality of life (HRQol) was assessed in 63 patients. Variations of diplopia or ptosis did not affect significantly physical (PCS) or mental composite subscores (MCS) of the Short-Form Health Survey (SF-36). Human leukocyte antigen (HLA) genotyping was studied to explore whether HLA class I and II allelic distribution differed among MG patients and controls. None of the studied HLA alleles significantly differed between OMG patients and controls. Similarly, none of the alleles with frequencies higher than 15% either in OMG patients or in controls was significantly associated, after Bonferroni correction, with the presence or absence of anti-AChR-Abs in serum.
Assuntos
Miastenia Gravis/diagnóstico , Prognóstico , Qualidade de Vida/psicologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Antígenos HLA/genética , Humanos , Masculino , Pessoa de Meia-Idade , Miastenia Gravis/genética , Miastenia Gravis/imunologia , Receptores Colinérgicos/imunologia , Índice de Gravidade de DoençaRESUMO
A 24-year-old female with 5 year history of heroin abuse experienced painless stiffness of elbow joints and weakness of shoulder and upper limb muscles. She was injecting herself 4-6 times daily alternatively in the upper extremities, sparing the lower limbs. Electromyography (EMG) showed myopathic changes in clinically affected and unaffected muscles. Magnetic resonance imaging (MRI) revealed muscle fibrosis in directly injected muscles, whereas in subcutaneous fat and within muscles of anterior and posterior compartments of both thighs, not directly injected, there were signal changes supportive of oedema and inflammation. EMG and MRI were congruent in showing abnormalities in muscles not directly injected, suggesting long distant effects of heroin or adulterants with a mechanism either toxic or immunologically mediated.
Assuntos
Dependência de Heroína/complicações , Músculo Esquelético/patologia , Doenças Musculares/etiologia , Diagnóstico Diferencial , Eletromiografia , Feminino , Fibrose/diagnóstico , Fibrose/etiologia , Humanos , Imageamento por Ressonância Magnética , Músculo Esquelético/fisiopatologia , Doenças Musculares/diagnóstico , Adulto JovemRESUMO
Hashimoto's encephalopathy is an often misdiagnosed, life threatening, condition which improves promptly with steroid therapy. Since clinical manifestations are heterogeneous and non-specific, the diagnosis is often difficult. Several case reports of Hashimoto's encephalopathy presenting with partial or generalised seizures are described, but only a few have focused on status epilepticus as the first clinical manifestation. We report two patients presenting with repetitive and prolonged seizures characterised by progressive reduction in contact and reactivity associated with frontal/diffuse polyspike-and-wave activities. This condition, which can be interpreted as a form of non-convulsive status epilepticus (NCSE) of frontal origin, was refractory to antiepileptic drugs but responded promptly to high doses of intravenous steroid treatment. In cases of unexplained encephalopathy with EEG documentation of NCSE, the early recognition and treatment of Hashimoto's encephalopathy may lead to a favourable prognosis. [Published with video sequences].
Assuntos
Encefalopatias/complicações , Doença de Hashimoto/complicações , Estado Epiléptico/etiologia , Idoso , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/uso terapêutico , Anticonvulsivantes/uso terapêutico , Encefalopatias/tratamento farmacológico , Catatonia/etiologia , Progressão da Doença , Eletroencefalografia , Encefalite , Feminino , Doença de Hashimoto/tratamento farmacológico , Humanos , Técnicas Imunoenzimáticas , Masculino , Pessoa de Meia-Idade , Estado Epiléptico/tratamento farmacológico , Estado Epiléptico/fisiopatologia , Esteroides/administração & dosagem , Esteroides/uso terapêutico , Testes de Função TireóideaAssuntos
Síndrome Miastênica de Lambert-Eaton/complicações , Leiomioma/complicações , Leiomioma/cirurgia , Neoplasias Uterinas/complicações , Neoplasias Uterinas/cirurgia , Neoplasias Vasculares/complicações , Neoplasias Vasculares/cirurgia , Adulto , Fadiga/etiologia , Feminino , Humanos , Histerectomia , Síndrome Miastênica de Lambert-Eaton/patologia , Síndrome Miastênica de Lambert-Eaton/fisiopatologia , Leiomioma/patologia , Leiomioma/fisiopatologia , Tomografia Computadorizada por Raios X , Resultado do Tratamento , Neoplasias Uterinas/patologia , Neoplasias Uterinas/fisiopatologia , Neoplasias Vasculares/patologia , Neoplasias Vasculares/fisiopatologia , Xerostomia/etiologiaAssuntos
Antirreumáticos/efeitos adversos , Miastenia Gravis/induzido quimicamente , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Idoso , Antirreumáticos/imunologia , Artrite Reumatoide/imunologia , Artrite Reumatoide/terapia , Feminino , Humanos , Miastenia Gravis/imunologia , Receptores do Fator de Necrose Tumoral/imunologia , Fator de Necrose Tumoral alfa/imunologiaRESUMO
A 40-year-old male developed swallowing difficulties, loss of strength, and imbalance. On admission, the patient exhibited bifacial, extremity weakness, ataxia, impaired sensation, and areflexia. Electrophysiology and nerve biopsy suggested demyelination. Spinal fluid revealed increased protein content. Plasmapheresis showed benefit, but neuropathy relapsed. At second recurrence, urine analysis showed heavy proteinuria. Renal biopsy revealed focal segmental glomerulosclerosis (FSGS). Methylprednisolone and oral cyclophosphamide were given. Long-term steroids and immunoglobulin showed steady benefit. Concurrence of chronic inflammatory demyelinating polyneuropathy and FSGS suggests synergistic cellular and humoral autoimmune mechanisms related to either cross-reactivity within antigenic targets or mimicry between neural and renal epitopes.